ORIGINAL RESEARCH PAPER
Volume - 14 | Issue - 03 | March - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

NEXT-GENERATION SEQUENCING IN INFECTIOUS DISEASE DIAGNOSTICS: ENHANCING RAPID PATHOGEN DETECTION AND ANTIMICROBIAL RESISTANCE SURVEILLANCE – A NARRATIVE REVIEW

Clinical Research

Medhansh Biradar*
MBBS Student, All India Institute of Medical Sciences, Raipur. *Corresponding Author

ABSTRACT

Next-generation sequencing (NGS) has transformed infectious disease diagnostics by enabling rapid, high-throughput pathogen identification and antimicrobial resistance (AMR) surveillance. Unlike traditional culture-based and targeted molecular methods, NGS offers a comprehensive, unbiased genomic analysis, facilitating early outbreak detection, epidemiological surveillance, and infection control. Its ability to identify both known and novel pathogens has proven invaluable during global health crises such as the COVID-19 pandemic, where whole-genome sequencing (WGS) played a critical role in variant tracking and vaccine development. Additionally, NGS enhances AMR surveillance by detecting resistance genes and mutations in real time, allowing for more precise antimicrobial therapy and improved stewardship programs. The integration of metagenomic sequencing into clinical workflows has further streamlined the identification of fastidious and polymicrobial infections, reducing diagnostic turnaround time and optimizing treatment strategies. However, widespread clinical adoption remains hindered by high costs, complex data interpretation, and the need for advanced bioinformatics infrastructure. Despite these challenges, ongoing advancements in cost-effective sequencing platforms, machine learning-driven analytics, and portable NGS technologies are making genomic surveillance more accessible. As these innovations continue to evolve, the incorporation of NGS into routine diagnostics and AMR monitoring will be crucial in addressing the growing threat of antimicrobial resistance and emerging infectious diseases, ultimately improving patient outcomes and informing global public health strategies.

KEYWORDS

Next-generation sequencing, infectious disease diagnostics, antimicrobial resistance, whole-genome sequencing, metagenomics, pathogen surveillance.

INTRODUCTION

The advent of next-generation sequencing (NGS) has revolutionized the field of infectious disease diagnostics, offering unprecedented capabilities for rapid pathogen detection and antimicrobial resistance (AMR) surveillance. Unlike traditional culture-based methods and molecular diagnostics, which are often time-consuming and limited in scope, NGS provides a comprehensive, high-throughput approach to characterizing microbial genomes with high sensitivity and specificity.**(1)** By enabling whole-genome sequencing (WGS) and metagenomic analyses, this transformative technology has significantly enhanced the speed and accuracy of identifying pathogenic organisms while simultaneously providing insights into their resistance mechanisms and evolutionary dynamics.**(2)**

The integration of NGS into clinical and public health microbiology has facilitated early outbreak detection, source tracing, and real-time monitoring of drug resistance, leading to more effective infection prevention and control strategies.**(3)** The ability to rapidly sequence and analyse microbial genomes has proven particularly valuable during global health crises, such as the COVID-19 pandemic, where it played a critical role in genomic epidemiology, variant tracking, and vaccine development.**(4)** Furthermore, NGS-based approaches have been instrumental in detecting emerging multidrug-resistant (MDR) pathogens, informing infection control measures, and guiding targeted antimicrobial therapy.**(5)**

With the increasing burden of AMR, particularly in acute care settings such as hospitals and intensive care units, the reliance on rapid molecular diagnostics has become more urgent than ever.**(6)** NGS offers a unique advantage in predicting resistance phenotypes through genotypic characterization of resistance genes, plasmids, and mobile genetic elements, thereby aiding in antimicrobial stewardship programs and optimizing empirical therapy.**(7)** Additionally, metagenomic sequencing enables the culture-independent identification of pathogens directly from clinical specimens, reducing diagnostic turnaround time and improving patient outcomes.**(8)**

Despite these advantages, several challenges hinder the widespread clinical adoption of NGS, including high costs, complex data interpretation, and the need for robust bioinformatics pipelines.**(9)** Nevertheless, ongoing advancements in sequencing technologies, computational tools, and machine learning applications are progressively addressing these barriers, making NGS more accessible and feasible for routine public health and clinical practice.**(10)** The implementation of NGS-based surveillance networks highlights the growing recognition of its potential in combating AMR at a global scale.

Thus, in a nutshell NGS represents a paradigm shift in infectious disease diagnostics and AMR surveillance. Its ability to provide rapid, comprehensive genomic insights has the potential to significantly improve patient outcomes, support infection control measures, and inform antibiotic stewardship efforts. As technological advancements continue to drive innovation in this field, the integration of NGS into routine diagnostic workflows will be essential in addressing the growing threat of antimicrobial resistance and emerging infectious diseases.

A. Overview of Next-Generation Sequencing (NGS) and its Significance in Infectious Disease Diagnostics

Next-generation sequencing (NGS) is revolutionizing infectious disease diagnostics by providing a rapid, unbiased method for pathogen identification. Unlike culture-based techniques or targeted molecular assays, NGS enables whole-genome sequencing within hours, offering insights into pathogen evolution, virulence factors, and antimicrobial resistance (AMR) mechanisms, critical for both clinical care and public health interventions.**(11)** A key advantage of NGS is its role in metagenomic studies, allowing the detection of both known and novel pathogens, including those difficult to culture. This broad-spectrum approach is particularly useful for polymicrobial infections, rare microorganisms, and outbreak investigations.**(12)**

Additionally, NGS facilitates real-time AMR surveillance by tracking resistance genes across populations, enabling early detection of emerging threats and guiding antimicrobial stewardship efforts.**(13)** Despite its transformative potential, challenges such as high costs, data complexity, and the need for bioinformatics expertise limit widespread clinical adoption. However, ongoing advancements in sequencing technology and computational tools are making NGS increasingly practical for routine use.**(14)** As these barriers are addressed, integrating NGS into diagnostics and surveillance programs will be crucial in combating antimicrobial resistance and improving patient outcomes

B. Advancements in Pathogen Detection

1. The Role of NGS in Identifying a Wide Range of Pathogens Rapidly

The advent of next-generation sequencing (NGS) has revolutionized infectious disease diagnostics by enabling the rapid identification of a wide range of pathogens. Unlike traditional methods that rely on time-consuming culturing, NGS provides a comprehensive analysis of microbial genetic material directly from clinical samples, allowing for the simultaneous detection of multiple organisms.**(15)** This capability is particularly crucial in acute clinical settings, where timely diagnosis can significantly impact treatment decisions. Additionally, NGS facilitates the assessment of antimicrobial resistance profiles, enhancing targeted therapy and infection control efforts. As clinical metagenomic NGS (mNGS) transitions from research to routine

diagnostics, advancements in sequencing technology and bioinformatics continue to improve its efficiency, making it an essential tool in modern infectious disease management.**(16)**

2. NGS in Culture-Independent Diagnostics

Traditional culture-based diagnostic techniques are often slow and limited by microbial growth requirements, making them less effective for detecting fastidious, slow-growing, or non-culturable organisms. Next-generation sequencing (NGS) overcomes these challenges by enabling the direct sequencing of microbial DNA or RNA from patient samples, allowing for more comprehensive and unbiased pathogen detection.**(9)** This approach is particularly valuable in polymicrobial infections, where conventional methods may miss key contributors. Additionally, NGS provides crucial insights into host-microbiome interactions, which can influence disease progression and treatment outcomes.**(17)**

3. Applications of NGS in Emerging and Re-Emerging Infectious Diseases

Next-generation sequencing (NGS) has been instrumental in identifying emerging and re-emerging infectious diseases. During the COVID-19 pandemic, whole-genome sequencing (WGS) played a crucial role in tracking SARS-CoV-2 variants, facilitating real-time epidemiological surveillance and informing vaccine development.**(18)** Similarly, NGS has been essential in detecting novel viral outbreaks, such as Zika and Ebola, enhancing outbreak response strategies by providing rapid genomic insights into pathogen evolution and transmission patterns.**(19)**

C. NGS in Antimicrobial Resistance Surveillance: Opportunities and Challenges

1. Utilizing NGS for Tracking and Understanding Antimicrobial Resistance Patterns

The integration of next-generation sequencing (NGS) into antimicrobial resistance (AMR) surveillance represents a transformative advancement in infectious disease management. Unlike traditional phenotypic methods, which are often time-consuming and may miss emerging resistance mechanisms, NGS enables comprehensive genomic analysis of pathogens, identifying genetic determinants of resistance with high precision. Whole-genome sequencing (WGS) of Neisseria gonorrhoeae, for example, has uncovered key mutations associated with antimicrobial resistance, shedding light on pathogen evolution and transmission dynamics.**(20)**

NGS-based approaches also bridge critical gaps in global AMR surveillance initiatives by facilitating large-scale tracking of resistance trends. Metagenomic sequencing further enhances this capability by allowing the direct detection of resistance genes from clinical and environmental samples without the need for culture, providing a more holistic understanding of the resistome.**(21)** The growing implementation of clinical metagenomic NGS (mNGS) in healthcare settings underscores its potential to revolutionize AMR monitoring and response efforts.**(22)**

2. Real-Time AMR Surveillance and Clinical Applications

The ability of NGS to perform real-time sequencing, combined with rapid bioinformatics analyses, enables early detection of resistance mutations, allowing for more precise antimicrobial therapy. By integrating NGS-based surveillance into clinical practice, hospitals and public health agencies can swiftly detect emerging resistance threats and implement targeted interventions. This approach has been particularly effective in genomic epidemiology studies of multidrug-resistant (MDR) bacterial outbreaks, where rapid sequencing has facilitated timely infection control measures.**(23)**

In addition to patient care, real-time AMR surveillance using NGS contributes to a proactive public health response. During outbreaks, sequencing data can reveal transmission patterns, helping to contain resistant strains before they become widespread. As sequencing costs decline and computational pipelines become more efficient, the integration of NGS into routine clinical workflows is expected to become increasingly feasible.**(24)**

3. Challenges and Considerations in Implementing NGS in Clinical Diagnostics

Despite its advantages, the widespread adoption of NGS in routine clinical diagnostics presents significant technical and analytical challenges. The sheer volume of sequencing data generated requires advanced bioinformatics tools for accurate interpretation, often necessitating specialized expertise in genomics and computational biology.**(25)** Standardizing bioinformatics pipelines is crucial to ensure reproducibility and minimize discrepancies in variant calling and resistance gene identification across different laboratories.**(26)**

Moreover, contamination risks in sequencing workflows can lead to false-positive or false-negative results, emphasizing the need for stringent quality control measures. Establishing validated protocols and integrating automated data analysis pipelines can enhance the reliability of NGS-based diagnostics.

4. Cost and Infrastructure Requirements

The implementation of NGS in clinical settings demands substantial financial investment, including high-throughput sequencing platforms, computational infrastructure, and trained personnel. The cost of sequencing and data storage remains a major barrier, particularly in resource-limited settings where laboratory infrastructure may not support advanced genomic technologies.**(27)** However, recent advancements in cost-effective sequencing methods, such as nanopore sequencing and portable sequencing devices, offer promising solutions to these challenges. These innovations have the potential to democratize NGS technology, making it more accessible for decentralized and point-of-care diagnostics. Continued efforts to optimize sequencing workflows and reduce costs will be key to integrating NGS into routine clinical and public health practice.**(28)**

CONCLUSION AND SUMMARY

NGS has emerged as a game-changing technology in AMR surveillance, offering unprecedented insights into pathogen evolution, resistance mechanisms, and outbreak dynamics. By enabling real-time tracking of resistance genes, NGS enhances both clinical decision-making and global public health responses. While challenges related to cost, infrastructure, and bioinformatics remain, ongoing advancements in sequencing technology and computational tools are making NGS increasingly practical for routine clinical use. As its adoption continues to expand, NGS will play a critical role in shaping the future of AMR surveillance and infectious disease management.

REFERENCES

1. Köser CU, Ellington MJ, Peacock SJ. Whole-genome sequencing to control antimicrobial resistance. Trends Genet. 2014 Sep 1;30(9):401–7.
2. Didelot X, Bowden R, Wilson DJ, Peto TEA, Crook DW. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet. 2012 Sep;13(9):601–12.
3. Towards a genomics-informed, real-time, global pathogen surveillance system | Nature Reviews Genetics [Internet]. [cited 2025 Mar 2]. Available from: https://www.nature.com/articles/nrg.2017.88
4. Oude Munnink BB, Worp N, Nieuwenhuijse DF, Sikkema RS, Haagmans B, Fouchier RAM, et al. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. Nat Med. 2021 Sep;27(9):1518–24.
5. Correction for Quainoo et al., "Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis" | Clinical Microbiology Reviews [Internet]. [cited 2025 Mar 2]. Available from: https://journals.asm.org/doi/10.1128/cmr.00082-17
6. Next-Generation Sequencing in Clinical Microbiology: Are We There Yet? - ScienceDirect [Internet]. [cited 2025 Mar 2]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0272271219300307?via%3Dihub
7. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, et al. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect. 2017 Jan 1;23(1):2–22.
8. Langelier C, Zinter MS, Kalantar K, Yanik GA, Christenson S, O'Donovan B, et al. Metagenomic Sequencing Detects Respiratory Pathogens in Hematopoietic Cellular Transplant Patients. Am J Respir Crit Care Med. 2018 Feb 15;197(4):524–8.
9. Rapid Whole-Genome Sequencing for Investigation of a Neonatal MRSA Outbreak | New England Journal of Medicine [Internet]. [cited 2025 Mar 2]. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1109910
10. Full article: Machine learning in infectious diseases: potential applications and limitations [Internet]. [cited 2025 Mar 2]. Available from: https://www.tandfonline.com/doi/full/10.1080/07853890.2024.2362869
11. Didelot X, Wilson DJ. ClonalFrameML: Efficient Inference of Recombination in Whole Bacterial Genomes. PLOS Comput Biol. 2015 Feb 12;11(2):e1004041.
12. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower respiratory infection | Nature Biotechnology [Internet]. [cited 2025 Mar 2]. Available from: https://www.nature.com/articles/s41587-019-0156-5
13. Kumar S, Nei M, Dudley J, Tamura K. MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform. 2008 Jul 1;9(4):299–306.
14. Bracken: estimating species abundance in metagenomics data [PeerJ] [Internet]. [cited 2025 Mar 2]. Available from: https://peerj.com/articles/cs-104/
15. Frontiers | Metagenomics: The Next Culture-Independent Game Changer [Internet]. [cited 2025 Mar 2]. Available from: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2017.01069/full
16. Simner PJ, Miller S, Carroll KC. Understanding the Promises and Hurdles of Metagenomic Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases. Clin Infect Dis. 2018 Feb 10;66(5):778–88.
17. Development and Optimization of an Unbiased, Metagenomics-Based Pathogen Detection Workflow for Infectious Disease and Biosurveillance Applications [Internet]. [cited 2025 Mar 2]. Available from: https://www.mdpi.com/2414-6366/8/2/121
18. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa | Nature [Internet]. [cited 2025 Mar 2]. Available from: https://www.nature.com/articles/

s41586-022-04411-y
19. Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, et al. Temporal and spatial analysis of the 2014–2015 Ebola virus outbreak in West Africa. Nature. 2015 Jun 17;524(7563):97.
20. Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS, Bentley SD, et al. Genomic Epidemiology of Gonococcal Resistance to Extended-Spectrum Cephalosporins, Macrolides, and Fluoroquinolones in the United States, 2000–2013. J Infect Dis. 2016 Nov 15;214(10):1579–87.
21. Lanza VF, Baquero F, Martínez JL, Ramos-Ruíz R, González-Zorn B, Andremont A, et al. In-depth resistome analysis by targeted metagenomics. Microbiome. 2018 Jan 15;6(1):11.
22. Rodino KG, Simner PJ. Status check: next-generation sequencing for infectious-disease diagnostics. J Clin Invest. 2024 Feb 15;134(4):e178003.
23. Aanensen DM, Feil EJ, Holden MTG, Dordel J, Yeats CA, Fedosejev A, et al. Whole-Genome Sequencing for Routine Pathogen Surveillance in Public Health: a Population Snapshot of Invasive Staphylococcus aureus in Europe. mBio. 2016 May 5;7(3):10.1128/mbio.00444-16.
24. Moran RA, Hall RM. Evolution of Regions Containing Antibiotic Resistance Genes in FII-2-FIB-1 ColV-Colla Virulence Plasmids. Microb Drug Resist Larchmt N. 2018 May;24(4):411–21.
25. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, et al. Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology. PLoS Pathog. 2012 Aug 2;8(8): e1002824.
26. O'Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2015 Nov 8;44(Database issue): D733.
27. Salazar AN, Nobrega FL, Anyansi C, Aparicio-Maldonado C, Costa AR, Haagsma AC, et al. An educational guide for nanopore sequencing in the classroom. PLoS Comput Biol. 2020 Jan 23;16(1): e1007314.
28. Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, et al. Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samples. Nat Protoc. 2017 May 24;12(6):1261.